Seattle biotech Kineta lands $4M contract to develop immunotherapy for infectious disease

The growing market for immunotherapy treatments isn't just focused on cancer. Seattle biotech Kineta just landed a federal contract from the National Institutes of Health for about $4 million to develop an immunotherapy treatment which would treat a variety of infectious diseases, such as the flu, dengue fever, Ebola and others. Kineta develops drugs for chronic pain, autoimmune and infectious diseases. The funding will be used to bring a specific drug candidate to the pre-clinical stage, with…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news